Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis

Apremilast is an orally available phosphodiesterase 4 inhibitor used for the treatment of moderate to severe psoriasis. The aims of this analysis were to develop a population pharmacokinetic (PPK) model of apremilast based on observed data from phase 1 studies combined with clinical trial data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Yukari, Ohtsuki, Mamitaro, Komine, Mayumi, Imafuku, Shinichi, Kassir, Nastya, Petric, Rosemary, Nemoto, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290614/
https://www.ncbi.nlm.nih.gov/pubmed/34396569
http://dx.doi.org/10.1111/1346-8138.16068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290614/
https://www.ncbi.nlm.nih.gov/pubmed/34396569
http://dx.doi.org/10.1111/1346-8138.16068

Ejemplares similares